Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  degarelix
Find trials that include:  Any drugs shown
Results 1-7 of 7 for your search:
Start Over
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
High-Dose Brachytherapy in Treating Patients with Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: PROS0065, NCI-2015-00089, 350, NCT02346253
Effects of Endocrine Therapy with or without Trametinib or Dasatinib in Patients with Localized, Untreated Prostate Cancer Undergoing Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-000714, NCI-2015-01448, EMT13001, NCI-2014-02414, NCT01990196
Enzalutamide versus Standard Androgen Deprivation Therapy in Reducing Incidence of Metabolic Syndrome in Patients with Advanced Prostate Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 19 and over
Trial IDs: 14-0909, NCI-2014-02219, NCT02278185
Androgen Receptor Antagonist ARN-509, Abiraterone Acetate, Prednisone, Degarelix, and Indomethacin in Treating Patients with Localized Prostate Cancer Before Surgery
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9628, NCI-2016-01027, NCT02849990
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients with Intermediate- or High-Risk Prostate Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-075, NCI-2015-00742, 1501013723, NCT02472275
Pembrolizumab and Cryosurgery in Treating Patients with Newly Diagnosed, Oligo-metastatic Prostate Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1534, NCI-2015-00981, IRB00045444, MK-3475, NCT02489357
Start Over